Literature DB >> 24277751

Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.

Akihiko Sokai1, Makiko Enaka, Risa Sokai, Shoichi Mori, Shunsuke Mori, Masaharu Gunji, Masahiko Fujino, Masafumi Ito.   

Abstract

Inflammatory myofibroblastic tumor is a rare tumor deriving from mesenchymal tissue. Approximately 50% of inflammatory myofibroblastic tumors harbor an anaplastic lymphoma kinase fusion gene. Pulmonary inflammatory myofibroblastic tumors harboring tropomyosin3-anaplastic lymphoma kinase or protein tyrosine phosphatase receptor-type F polypeptide-interacting protein-binding protein 1-anaplastic lymphoma kinase have been reported previously. However, it has not been reported that inflammatory myofibroblastic tumors harbor echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene which is considered to be very specific to lung cancers. A few tumors harboring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene other than lung cancers have been reported and the tumors were all carcinomas. A 67-year-old man had been followed up for a benign tumor for approximately 3 years before the tumor demonstrated malignant transformation. Lobectomy and autopsy revealed that an inflammatory myofibroblastic tumor harboring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene had transformed into an undifferentiated sarcoma. This case suggests that echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion is an oncogenic event in not only carcinomas but also sarcomas originating from stromal cells.

Entities:  

Keywords:  EML4-ALK; inflammatory myofibroblastic tumor; malignant transformation

Mesh:

Substances:

Year:  2013        PMID: 24277751     DOI: 10.1093/jjco/hyt173

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  10 in total

1.  Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Authors:  Cristina R Antonescu; Albert J H Suurmeijer; Lei Zhang; Yun-Shao Sung; Achim A Jungbluth; William D Travis; Hikmat Al-Ahmadie; Christopher D M Fletcher; Rita Alaggio
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

2.  For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.

Authors:  Diana Taheri; David J Zahavi; Maria Del Carmen Rodriguez; Abdelrazak Meliti; Neda Rezaee; Raluca Yonescu; Bernardo F P Ricardo; Shahaboddin Dolatkhah; Yi Ning; Justin A Bishop; George J Netto; Rajni Sharma
Journal:  Virchows Arch       Date:  2016-06-06       Impact factor: 4.064

3.  Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.

Authors:  Longfei Zhu; Jian Li; Chengwu Liu; Wenshuang Ding; Feng Lin; Chenglin Guo; Lunxu Liu
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.

Authors:  Jon H Chung; Siraj M Ali; Jenni Davis; Karl Robstad; Richard McNally; Laurie M Gay; Rachel L Erlich; Norma A Palma; Phil J Stephens; Vincent A Miller; Alfonso Cutugno; Jeffrey S Ross
Journal:  Case Rep Oncol       Date:  2014-09-09

5.  Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Quan Jiang; Han-Xing Tong; Ying-Yong Hou; Yong Zhang; Jing-Lei Li; Yu-Hong Zhou; Jing Xu; Jiong-Yuan Wang; Wei-Qi Lu
Journal:  Orphanet J Rare Dis       Date:  2017-05-23       Impact factor: 4.123

6.  Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.

Authors:  Mukesh Bansal; Jing He; Michael Peyton; Manjunath Kustagi; Archana Iyer; Michael Comb; Michael White; John D Minna; Andrea Califano
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

7.  Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature.

Authors:  Qianqian Han; Xin He; Lijuan Cui; Yan Qiu; Yuli Li; Huijiao Chen; Hongying Zhang
Journal:  Front Med (Lausanne)       Date:  2022-02-24

8.  Limited airway resection and reconstruction for paediatric tracheobronchial inflammatory myofibroblastic tumour.

Authors:  Junguo Dong; Diego Gonzalez-Rivas; Pengcheng Lv; Zhexin Wang; Jiaxi He; Feng Yao; Shuben Li
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-08-03

Review 9.  Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.

Authors:  Jerzy Lasota; Małgorzata Chłopek; Bartosz Wasąg; Artur Kowalik; Jason Christiansen; Jennifer Lamoureux; Alina Kuźniacka; Anna Felisiak-Gołąbek; Yalan Liu; Tiffany Ashley R Reyes; Rishabh Saha; Abbas Agaimy; Kristyna Behenska; Wojciech Biernat; Laura Cattaneo; Giovanni Centonze; Ondrej Daum; Magdalena Daumova; Paweł Domagała; Ireneusz Dziuba; Carol E Geppert; Stanisław Góźdź; Anna Nasierowska-Guttmejer; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Janusz Ryś; Piotr Waloszczyk; Jaroslaw Wejman; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2020-09       Impact factor: 6.298

10.  Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature.

Authors:  Hidehiro Watanabe; Tomonori Uruma; Gen Tazaki; Takuma Tajiri; Ryota Kikuchi; Masayuki Itoh; Kazutetsu Aoshiba; Hiroyuki Nakamura
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.